AstraZeneca plc Stock Rating Reaffirmed by Deutsche Bank (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reiterated by investment analysts at Deutsche Bank in a note issued to investors on Monday, American Banking News.com reports. They currently have a GBX 3,800 ($64.01) price target on the stock. Deutsche Bank’s price target points to a potential downside of 21.22% from the stock’s previous close.
AstraZeneca plc (LON:AZN) traded up 2.05% during mid-day trading on Monday, hitting GBX 4823.50. 6,188,799 shares of the company’s stock traded hands. AstraZeneca plc has a 1-year low of GBX 3028.50 and a 1-year high of GBX 5750.00. The stock’s 50-day moving average is GBX 4211.81 and its 200-day moving average is GBX 3828.. The company’s market cap is £60.824 billion.
A number of other firms have also recently commented on AZN. Analysts at Barclays reiterated an “equal weight” rating on shares of AstraZeneca plc in a research note on Friday, May 9th. They now have a GBX 3,800 ($64.01) price target on the stock. Separately, analysts at Panmure Gordon reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Wednesday, May 7th. They now have a GBX 5,400 ($90.96) price target on the stock. Finally, analysts at Societe Generale reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, May 7th. They now have a GBX 4,661 ($78.51) price target on the stock. Six research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of GBX 3,995.73 ($67.30).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.